期刊文献+

不同剂量CRRT对危重患者血乳酸清除的影响 被引量:1

Effect of different doses of continuous renal replacement therapy(CRRT) on blood lactate clearance in critical patients
下载PDF
导出
摘要 目的观察不同剂量持续性肾脏替代治疗(CRRT)对危重患者血乳酸(BLa)清除程度的影响。方法 24例危重患者根据BLa水平归入4组(A组:BLa<2 mmol/L;B组:2 mmol/L≤BLa<4 mmol/L;C组:4 mmol/L≤BLa<8 mmol/L;D组:BLa≥8 mmol/L),每组依次接受25、35、45 m L/(kg·h)剂量的CRRT,每次1 h。根据CRRT前后BLa浓度计算BLa清除率及清除量。结果同组中CRRT剂量越大,BLa清除率越大(P<0.05或0.01),但BLa清除量差异无统计学意义(P>0.05)。相同CRRT剂量时,各组BLa清除率差异无统计学意义(P>0.05),但C、D组BLa清除量明显大于A、B组(P<0.05或0.01)。结论 CRRT剂量影响危重患者BLa清除率,而初始BLa水平影响乳酸清除量。 Objective To observe the impact of different doses of continuous renal replacement therapy(CRRT) on blood lactate(BLa) clearance in critical patients. Methods Twenty-four critical patients were categorized into 4 groups based on their BLa levels(Group A: BLa〈2 mmol/L; Group B:2 mmol/L≤BLa〈4 mmol/L; Group C:4 mmol/L≤BLa〈8 mmol/L; Group D: BLa≥8 mmol/L). Each group received in turn 25,35,and 45 m L/(kg·h) of CRRT for 1 hour. The clearance rate and volume of BLa were calculated using BLa levels of pre- and post-CRRT. Results In the same group,BLa clearance rates were increased with CRRT doses(P〈0.01 or 0.05),but BLa clearance volumes were not(P〈0.05). In the same CRRT dose,BLa clearance rates were similar among all groups(P〈0.05),whereas BLa clearance volumes were higher in Groups C and D than in Groups A and B(P〈0.01 or 0.05). Conclusion The BLa clearance rates and volumes can be dependent on the CRRT doses and initial BLa contents,respectively.
出处 《广东医学院学报》 2015年第6期702-704,共3页 Journal of Guangdong Medical College
基金 广东省湛江市科研项目(No.2013B01105)
关键词 持续性肾脏替代治疗 血乳酸 continuous renal replacement therapy blood lactate
  • 相关文献

参考文献6

二级参考文献15

  • 1严静.成人严重感染与感染性休克血流动力学监测与支持指南(2006)[J].中国实用外科杂志,2007,27(1):7-13. 被引量:132
  • 2雷闽湘,张巾超.内分泌学.北京:人民卫生出版社,2006:1535.
  • 3Chang CT, Chen YC, Fang JT, et al. Metformin - associated lactic acidosis : case reports and literature review. J Nephro1,2002,15 ( 2 ) : 398 - 402.
  • 4United Kingdom Prospective Diabetes Study Group. Effect of inten- sive blood -glucose control with mefformin on complications in over- weight patients with type 2 diabetes ( UKPDS 34). Lancet, 1998,352 (9131) :854 - 865.
  • 5Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initi- ation and adjustment of therapy: a consensus statement of the Ameri- can Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2009,32 ( 1 ) :193 -203.
  • 6Stades AM, Heikens JT, Erkelens DW, et al. Metformin and lactic acidosis: cause or coincidence.'? A review of case reports. J Intern Med,2004,255 (2) :179 - 187.
  • 7Peters N, Jay N, Barraud D, et al. Metformin - associated lactic aci- dosis in an intensive care unit. Crit Care, 2008,12(6) :R149.
  • 8Bruijstens LA, van Luin M, Buscher - Jungerhans PM, et al. Real- ity of severe mefformin - induced lactic acidosis in the absence of chronic renal impairment. Neth J Med,2008,66(5) :185 - 190.
  • 9Dellinger R P, Cadet J M, Masur H, et al. Surviving sepsis campaign guidelines for management of sevelt sepsis and septic shock [J]. Crit Care Med, 2004,32(3):858-873.
  • 10Bakker J. Lactate: May I have your votes please [J ] ? Intensive Care Med, 2001,27 ( 1 ) : 6-11.

共引文献60

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部